# Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

> **NCT01578889** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 100 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** HIV-MAG vaccine
- **BIOLOGICAL:** IL-12 pDNA adjuvant
- **BIOLOGICAL:** VSV HIV gag vaccine
- **BIOLOGICAL:** Placebo
- **DEVICE:** Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device

## Key facts

- **NCT ID:** NCT01578889
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2014-09
- **Final completion:** 2016-10
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2021-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01578889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01578889, "Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01578889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*